{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T02:09:12Z","timestamp":1785550152705,"version":"3.56.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,21]],"date-time":"2020-01-21T00:00:00Z","timestamp":1579564800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"ational Major Scientific and Technological Special Project","award":["2018ZX10302104), and the C"],"award-info":[{"award-number":["2018ZX10302104), and the C"]}]},{"name":"hongqing Municipal Health and Family Planning Commission Medical Research Projects (","award":["ZY201702045,"],"award-info":[{"award-number":["ZY201702045,"]}]},{"name":"hongqing Municipal Health and Family Planning Commission Medical Research Projects (","award":["ZY201702047, and"],"award-info":[{"award-number":["ZY201702047, and"]}]},{"name":"hongqing Municipal Health and Family Planning Commission Medical Research Projects (","award":["ZY201702049)"],"award-info":[{"award-number":["ZY201702049)"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.ijid.2020.01.035","type":"journal-article","created":{"date-parts":[[2020,1,24]],"date-time":"2020-01-24T21:51:52Z","timestamp":1579902712000},"page":"108-117","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"special_numbering":"C","title":["Efficacy and safety of the regimens containing tenofovir alafenamide versus tenofovir disoproxil fumarate in fixed-dose single-tablet regimens for initial treatment of HIV-1 infection: A meta-analysis of randomized controlled trials"],"prefix":"10.1016","volume":"93","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5533-5877","authenticated-orcid":false,"given":"Xingbao","family":"Tao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqiu","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lvlang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3229-0108","authenticated-orcid":false,"given":"Yaokai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ijid.2020.01.035_bib0005","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1517\/14656566.2012.642865","article-title":"Combination nucleoside\/nucleotide reverse transcriptase inhibitors for treatment of HIV infection","volume":"13","author":"Akanbi","year":"2012","journal-title":"Expert Opin Pharmaco"},{"issue":"1","key":"10.1016\/j.ijid.2020.01.035_bib0010","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1185\/03007995.2013.844685","article-title":"Single-tablet regimens in HIV: does it really make a difference?","volume":"30","author":"Aldir","year":"2014","journal-title":"Curr Med Res Opin"},{"issue":"7","key":"10.1016\/j.ijid.2020.01.035_bib0015","doi-asserted-by":"crossref","first-page":"687","DOI":"10.3851\/IMP2770","article-title":"Tenofovir alafenamide is not a substrate for renal organic anion transporters (OATs) and does not exhibit OAT-dependent cytotoxicity","volume":"19","author":"Bam","year":"2014","journal-title":"Antivir Ther"},{"issue":"7","key":"10.1016\/j.ijid.2020.01.035_bib0020","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/QAD.0b013e32835192ae","article-title":"Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents","volume":"26","author":"Bedimo","year":"2012","journal-title":"Aids"},{"issue":"6","key":"10.1016\/j.ijid.2020.01.035_bib0025","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.3851\/IMP2305","article-title":"Switching to tenofovir\/emtricitabine from abacavir\/lamivudine in HIV-infected adults with raised cholesterol: effect on lipid profiles","volume":"17","author":"Behrens","year":"2012","journal-title":"Antivir Ther"},{"issue":"17","key":"10.1016\/j.ijid.2020.01.035_bib0030","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1097\/QAD.0b013e32801022eb","article-title":"Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review","volume":"20","author":"Brown","year":"2006","journal-title":"Aids"},{"issue":"11","key":"10.1016\/j.ijid.2020.01.035_bib0035","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1093\/cid\/cir628","article-title":"Premature aging and premature age-related comorbidities in HIV-infected patients: facts and hypotheses","volume":"53","author":"Capeau","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.ijid.2020.01.035_bib0040","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1161\/CIRCULATIONAHA.109.898585","article-title":"Association between kidney function and albuminuria with cardiovascular events in HIV-infected persons","volume":"121","author":"Choi","year":"2010","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.ijid.2020.01.035_bib0045","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3018(17)30032-2","volume":"4","author":"DeJesus","year":"2017","journal-title":"Lancet Hiv"},{"issue":"11","key":"10.1016\/j.ijid.2020.01.035_bib0050","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1097\/QAD.0000000000001817","article-title":"A week-48 randomized phase-3 trial of darunavir\/cobicistat\/emtricitabine\/tenofovir alafenamide in treatment-naive HIV-1 patients","volume":"32","author":"Eron","year":"2018","journal-title":"Aids"},{"issue":"6","key":"10.1016\/j.ijid.2020.01.035_bib0055","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1345\/aph.1C427","article-title":"Factors affecting patient adherence to highly active antiretroviral therapy","volume":"37","author":"Escobar","year":"2003","journal-title":"Ann Pharmacother"},{"issue":"10","key":"10.1016\/j.ijid.2020.01.035_bib0060","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1093\/cid\/cit538","article-title":"Low Baseline CD4(+) count is associated with greater bone mineral density loss after antiretroviral therapy initiation","volume":"57","author":"Grant","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10.1016\/j.ijid.2020.01.035_bib0065","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1097\/QAD.0b013e32832c1792","article-title":"Continuous antiretroviral therapy decreases bone mineral density","volume":"23","author":"Grund","year":"2009","journal-title":"Aids"},{"issue":"11","key":"10.1016\/j.ijid.2020.01.035_bib0070","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1093\/cid\/cir627","article-title":"Premature age-related comorbidities among HIV-infected persons compared with the general population","volume":"53","author":"Guaraldi","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10.1016\/j.ijid.2020.01.035_bib0075","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1089\/aid.2013.0048","article-title":"Plasma klotho levels were inversely associated with subclinical carotid atherosclerosis in HIV-infected patients receiving combined antiretroviral therapy","volume":"29","author":"Jeong","year":"2013","journal-title":"Aids Res Hum Retrov"},{"issue":"5","key":"10.1016\/j.ijid.2020.01.035_bib0080","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1093\/jac\/dkt532","article-title":"Phase I\/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults","volume":"69","author":"Markowitz","year":"2014","journal-title":"J Antimicrob Chemoth"},{"issue":"5","key":"10.1016\/j.ijid.2020.01.035_bib0085","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1007\/s10067-014-2627-x","article-title":"Hypophosphatemic osteomalacia induced by tenofovir in HIV-infected patients","volume":"35","author":"Mateo","year":"2016","journal-title":"Clin Rheumatol"},{"issue":"12","key":"10.1016\/j.ijid.2020.01.035_bib0090","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1093\/infdis\/jir188","volume":"203","author":"McComsey","year":"2011","journal-title":"J Infect Dis"},{"issue":"4","key":"10.1016\/j.ijid.2020.01.035_bib0095","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/QAI.0000000000000618","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate in the first protease inhibitor-based single-tablet regimen for initial HIV-1 therapy: a randomized phase 2 study","volume":"69","author":"Mills","year":"2015","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"11","key":"10.1016\/j.ijid.2020.01.035_bib0100","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1097\/QAD.0b013e328339fe53","article-title":"Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients","volume":"24","author":"Mocroft","year":"2010","journal-title":"Aids"},{"issue":"6","key":"10.1016\/j.ijid.2020.01.035_bib0105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0066223","article-title":"Role of traditional risk factors and antiretroviral drugs in the incidence of chronic kidney disease, ANRS CO3 aquitaine cohort, France, 2004-2012","volume":"8","author":"Morlat","year":"2013","journal-title":"Plos One"},{"key":"10.1016\/j.ijid.2020.01.035_bib0110","article-title":"Week 96 results of a phase 3 trial of darunavir\/cobicistat\/emtricitabine\/tenofovir alafenamide in treatment-naive HIV-1 patients","author":"Orkin","year":"2019","journal-title":"Aids"},{"issue":"9","key":"10.1016\/j.ijid.2020.01.035_bib0115","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.2174\/138161206776055840","article-title":"Current HIV treatment guidelines--an overview","volume":"12","author":"Rathbun","year":"2006","journal-title":"Curr Pharm Des"},{"issue":"1","key":"10.1016\/j.ijid.2020.01.035_bib0120","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/QAI.0000000000000225","article-title":"Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study","volume":"67","author":"Sax","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"9987","key":"10.1016\/j.ijid.2020.01.035_bib0125","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1016\/S0140-6736(15)60616-X","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials","volume":"385","author":"Sax","year":"2015","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.ijid.2020.01.035_bib0130","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1086\/656417","article-title":"Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study","volume":"51","author":"Stellbrink","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2020.01.035_bib0135","doi-asserted-by":"crossref","first-page":"33","DOI":"10.7448\/IAS.15.6.18104","article-title":"Self-reported adherence supports patient preference for the single tablet regimen (STR) in the current cART era","volume":"15","author":"Sterrantino","year":"2012","journal-title":"J Int Aids Soc"},{"key":"10.1016\/j.ijid.2020.01.035_bib0140","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ijid.2019.07.011","article-title":"Virologically suppressed HIV-infected patients on TDF-containing regimens significantly benefit from switching to TAF-containing regimens: a meta-analysis of randomized controlled trials","volume":"87","author":"Tao","year":"2019","journal-title":"Int J Infect Dis"},{"issue":"9","key":"10.1016\/j.ijid.2020.01.035_bib0145","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1128\/AAC.00350-08","article-title":"Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects","volume":"52","author":"Van Rompay","year":"2008","journal-title":"Antimicrob Agents Ch"},{"key":"10.1016\/j.ijid.2020.01.035_bib0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1468-1293.2012.01029.x","article-title":"British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012","volume":"13","author":"Williams","year":"2012","journal-title":"Hiv Med"},{"issue":"1","key":"10.1016\/j.ijid.2020.01.035_bib0155","first-page":"58","article-title":"A Randomized, double-blind comparison of tenofovir alafenamide versus tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine for initial HIV-1 treatment: week 96 results","volume":"72","author":"Wohl","year":"2016","journal-title":"Jaids-J Acq Imm Def"},{"issue":"1","key":"10.1016\/j.ijid.2020.01.035_bib0160","first-page":"73","article-title":"Microalbuminuria is associated with all-cause and AIDS mortality in women with HIV infection","volume":"55","author":"Wyatt","year":"2010","journal-title":"Jaids-J Acq Imm Def"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971220300370?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971220300370?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:48:36Z","timestamp":1761119316000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971220300370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":32,"alternative-id":["S1201971220300370"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2020.01.035","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of the regimens containing tenofovir alafenamide versus tenofovir disoproxil fumarate in fixed-dose single-tablet regimens for initial treatment of HIV-1 infection: A meta-analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2020.01.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}]}}